, Tracking Stock Market Picks
Enter Symbol:

down 3.20 %

CELL THERAPEUTICS (CTIC) rated Buy by ThinkEquity

Posted on: Monday,  Oct 15, 2012  9:25 AM ET by ThinkEquity

ThinkEquity rated Buy CELL THERAPEUTICS (NASDAQ: CTIC) on 10/15/2012, when the stock price was $1.56. Since
then, CELL THERAPEUTICS has lost 3.21% as of 01/07/2016's recent price of $1.51.
If you would have followed this ThinkEquity's recommendation on CTIC, you would have lost 3.2% of your investment in 1179 days.

Cell Therapeutic developing, acquiring and commercializing novel treatments for cancer. Our goal is to build a leading, vertically-integrated biopharmaceutical company with a diversified portfolio of oncology drugs and drug candidates. The company's research and in-licensing activities are concentrated on identifying new, less toxic and more effective ways to treat cancer. The company has received fast-track designation from the FDA for this indication and expect to receive priority review, which would expedite the FDA's review of our application.

Research is at the core of everything we do at ThinkEquity, and we're passionate about it. Employing a disciplined and rigorous process, we scrutinize the spectrum of forces at play in the growth sectors we cover. Starting with a top down analysis, we look closely at the megatrends and industry drivers that create opportunities for innovative companies. We then allocate our resources based on a long-range research roadmap that leads to deep domain expertise and a close working knowledge of the technologies, products, services and people that populate the growth sector landscape. In short, the sum result of the ThinkEquity research process is to identify and affiliate ourselves with the fastest growing private and public companies within our domain verticals.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/15/2012 9:25 AM Buy
as of 12/31/2012
1 Week   
1 Month down  -5.79 %
3 Months down  -16.66 %
1 YTD down  -16.66 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy